Metraipolis › archive › dc_65055cdd2465
Clinical and radiographic prognostic factors in recurrent contrast-enhancing IDH-mutant gliomas treated with bevacizumab — Europe PMC PMID:42046772
- Source
- Europe PMC (en)
- Original
- https://europepmc.org/article/MED/42046772
- DOI
- 10.1093/noajnl/vdag089
- License (as archived)
- solo-consultazione
- Archived
- 2026-10-08T15:16:23.663Z
- SHA-256 of the archived text
d2d0b2ad4b8da18703654e6a8030ebd41967c46cc99a28e21f49d62c0178b448- Stable URL of this page
https://metraipolis.com/documento/dc_65055cdd2465
How to cite
Clinical and radiographic prognostic factors in recurrent contrast-enhancing IDH-mutant gliomas treated with bevacizumab — Europe PMC PMID:42046772 — Europe PMC (en), https://europepmc.org/article/MED/42046772 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_65055cdd2465 (Metraipolis archive dc_65055cdd2465, sha256 d2d0b2ad4b8da18703654e6a8030ebd41967c46cc99a28e21f49d62c0178b448)
BibTeX
@misc{dc65055cdd2465,
title = {Clinical and radiographic prognostic factors in recurrent contrast-enhancing IDH-mutant gliomas treated with bevacizumab — Europe PMC PMID:42046772},
howpublished = {Europe PMC (en)},
url = {https://europepmc.org/article/MED/42046772},
note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_65055cdd2465; sha256 d2d0b2ad4b8da18703654e6a8030ebd41967c46cc99a28e21f49d62c0178b448},
year = {2026}
}Archived text
The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42046772. Agents can read the archived copy with the MCP tool read_document.